A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.

BACKGROUND Pre-transplant donor-specific anti-human leucocyte antigen (HLA) antibodies (DSAs) are associated with impaired kidney graft survival while the clinical relevance of non-donor-specific anti-HLA antibodies (nDSAs) is more controversial. The aim of the present paired kidney graft study was to compare the clinical relevance of DSAs and nDSAs. METHODS To eliminate donor and era-dependent factors, a post hoc paired kidney graft analysis was performed as part of a Dutch multicentre study evaluating all transplantations between 1995 and 2005 with available pre-transplant serum samples. Anti-HLA antibodies were detected with a Luminex single-antigen bead assay. RESULTS Among 3237 deceased donor transplantations, we identified 115 recipient pairs receiving a kidney from the same donor with one recipient being DSA positive and the other without anti-HLA antibodies. Patients with pre-transplant DSAs had a significantly lower 10-year death-censored graft survival (55% versus 82%, P=0.0001). We identified 192 pairs with one recipient as nDSA positive (against Class I and/or II) and the other without anti-HLA antibodies. For the patients with nDSAs against either Class I or II, graft survival did not significantly differ compared with patients without anti-HLA antibodies (74% versus 77%, P = 0.79). Only in patients with both nDSAs Class I and II was there a trend towards a lower graft survival (58%, P = 0.06). Lastly, in a small group of 42 recipient pairs, 10-year graft survival in recipients with DSAs was 49% compared with 68% in recipients with nDSAs (P=0.11). CONCLUSION This paired kidney analysis confirms that the presence of pre-transplant DSAs in deceased donor transplantations is a risk marker for graft loss, whereas nDSAs in general are not associated with a lower graft survival. Subgroup analysis indicated that only in broadly sensitized patients with nDSAs against Class I and II, nDSAs may be a risk marker for graft loss in the long term.

[1]  M. Verhaar,et al.  FP704A PAIRED KIDNEY ANALYSIS ON THE IMPACT OF ANTI-HLA ANTIBODIES ON GRAFT SURVIVAL , 2018 .

[2]  M. Bots,et al.  Differential effects of donor‐specific HLA antibodies in living versus deceased donor transplant , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  Rubin Zhang.  Donor-Specific Antibodies in Kidney Transplant Recipients. , 2018, Clinical journal of the American Society of Nephrology : CJASN.

[4]  A. Cabrita,et al.  Impact on mid-term kidney graft outcomes of pretransplant anti-HLA antibodies detected by solid-phase assays: Do donor-specific antibodies tell the whole story? , 2017, Human immunology.

[5]  D. Roelen,et al.  A Memory B Cell Crossmatch Assay for Quantification of Donor‐Specific Memory B Cells in the Peripheral Blood of HLA‐Immunized Individuals , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  B. Banas,et al.  Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  J. Farber,et al.  The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies , 2016, Journal of immunology research.

[8]  N. Lachmann,et al.  Tracing clinically relevant HLA antibodies prior to kidney transplantation: Commentary on “Pre‐transplant HLA antibodies detected by single antigen bead assay are a risk factor for long‐term kidney graft loss even in the absence of donor specific antibodies” , 2016, Transplant International.

[9]  E. Seifried,et al.  Pretransplant human leukocyte antigen antibodies detected by single‐antigen bead assay are a risk factor for long‐term kidney graft loss even in the absence of donor‐specific antibodies , 2016, Transplant international : official journal of the European Society for Organ Transplantation.

[10]  S. Lepreux,et al.  Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation , 2016, Transplantation.

[11]  V. Sharma,et al.  Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure , 2015, Transplantation.

[12]  J. Chapman,et al.  Peak Panel Reactive Antibody, Cancer, Graft, and Patient Outcomes in Kidney Transplant Recipients , 2015, Transplantation.

[13]  M. Bots,et al.  The PROCARE consortium: toward an improved allocation strategy for kidney allografts. , 2014, Transplant immunology.

[14]  L. Szydlowski,et al.  Effect of recipient sensitization (peak panel reactive antibodies) on 15-year survival after kidney transplantation. , 2014, Transplantation proceedings.

[15]  J. Pascual,et al.  Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? , 2013, Transplant immunology.

[16]  P. Aljama,et al.  Long-term allograft survival after kidney transplantation. , 2013, Transplantation proceedings.

[17]  Carmine Zoccali,et al.  When do we need competing risks methods for survival analysis in nephrology? , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[19]  F. Christiansen,et al.  Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. , 2013, Transplant immunology.

[20]  C. Haisch,et al.  Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts , 2013, Transplantation.

[21]  L. Racusen,et al.  The Banff classification revisited. , 2013, Kidney international.

[22]  L. Ratner,et al.  Donor-specific antibodies adversely affect kidney allograft outcomes. , 2012, Journal of the American Society of Nephrology : JASN.

[23]  M. Clatworthy,et al.  Preformed Donor HLA‐DP‐Specific Antibodies Mediate Acute and Chronic Antibody‐Mediated Rejection Following Renal Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  E. Akalin,et al.  Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients. , 2012, Human immunology.

[25]  M. Verhaar,et al.  Pretransplant Donor‐Specific HLA Class‐I and ‐II Antibodies Are Associated With an Increased Risk for Kidney Graft Failure , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  S. Thomas,et al.  A Novel ELISPOT Assay to Quantify HLA‐Specific B Cells in HLA‐Immunized Individuals , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  M. González-Escribano,et al.  Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  Carly J. Callender,et al.  Frequency of HLA-DP-specific antibodies and a possible new cross-reacting group. , 2012, Human Immunology.

[29]  J. Schold,et al.  Impact of Cold Ischemia Time on Graft Survival Among ECD Transplant Recipients: A Paired Kidney Analysis , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  C. Roufosse,et al.  Outcome of Patients with Preformed Donor‐Specific Antibodies Following Alemtuzumab Induction and Tacrolimus Monotherapy , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  Dominique Charron,et al.  Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. , 2010, Journal of the American Society of Nephrology : JASN.

[32]  P. Reinke,et al.  Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts , 2009, Transplantation.

[33]  P. Sinnott,et al.  Pretransplant Donor-Specific Antibodies in Cytotoxic Negative Crossmatch Kidney Transplants: Are They Relevant? , 2008, Transplantation.

[34]  Malek Kamoun,et al.  Preformed donor-directed anti-HLA-DP antibodies may be an impediment to successful kidney transplantation. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  P. Terasaki,et al.  Development of Nondonor‐Specific HLA‐DR Antibodies in Allograft Recipients Is Associated with Shared Epitopes with Mismatched Donor DR Antigens , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[36]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[37]  E. Reed,et al.  Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. , 2013, Methods in molecular biology.